Literature DB >> 23259425

Immunosuppression and risk of cervical cancer.

Pierre-Antoine Dugué1, Matejka Rebolj, Peter Garred, Elsebeth Lynge.   

Abstract

A markedly increased risk of cervical cancer is known in women immunosuppressed due to AIDS or therapy following organ transplantation. The aim of this review is to determine the association between other conditions affecting the immune system and the risk of cervical cancer. Patients with end-stage renal disease seem to be at an increased risk of cervical cancer. A higher risk of cervical precancerous lesions was found in patients with some autoimmune diseases; particularly if treated with immunosuppressants. Among behavioral factors weakening the immune system, smoking appeared to strongly increase the risk of cervical cancer, while poor diet only moderately increased the risk. It is difficult to determine whether sexually transmitted infections other than human papillomavirus infection are independent risk factors. Identifying those groups of women likely to fail in clearing persistent human papillomavirus infections would help individualize screening guidelines and target immune-associated factors in the cervical cancer etiology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23259425     DOI: 10.1586/era.12.159

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  22 in total

Review 1.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 2.  An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Authors:  Stephanie C Casey; Yulin Li; Dean W Felsher
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

3.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

4.  Women diagnosed with HIV and unknown HIV status perceived susceptibility to cervical cancer and perceived benefits of cervical cancer screening in Ghana: a cross-sectional study.

Authors:  Nancy Innocentia Ebu Enyan; Selorm Akaba; Sarah Ama Amoo
Journal:  BMC Womens Health       Date:  2021-10-17       Impact factor: 2.809

5.  Characterization and clinical management of abnormal cytology findings in pregnant women: a retrospective analysis.

Authors:  Rosa Freudenreich; Martin Weiss; Tobias Engler; Felix Neis; Melanie Henes
Journal:  Arch Gynecol Obstet       Date:  2022-08-17       Impact factor: 2.493

6.  Human papillomavirus vaccination uptake among childhood cancer survivors in Western New York.

Authors:  Melany Garcia; Cailey McGillicuddy; Elisa M Rodriguez; Kristopher Attwood; Jennifer Schweitzer; Scott Coley; Denise Rokitka; Nicolas F Schlecht
Journal:  Pediatr Blood Cancer       Date:  2022-09-12       Impact factor: 3.838

7.  Behavioral and clinical factors associated with self-reported abnormal Papanicolaou tests in rheumatoid arthritis.

Authors:  Victoria G Gillet; Daniel H Solomon; Nancy A Shadick; Michael E Weinblatt; Christine K Iannaccone; Sarah Feldman; Seoyoung C Kim
Journal:  J Womens Health (Larchmt)       Date:  2014-09       Impact factor: 2.681

Review 8.  Insight to drug delivery aspects for colorectal cancer.

Authors:  Arvind Gulbake; Aviral Jain; Ashish Jain; Ankit Jain; Sanjay K Jain
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 9.  [Gynecological cancers in patients with inflammatory rheumatic diseases].

Authors:  M Schmalzing; M Krockenberger; A Honig; H-P Tony
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

Review 10.  A Review on Inosine Pranobex Immunotherapy for Cervical HPV-Positive Patients.

Authors:  Stefan Miladinov Kovachev
Journal:  Infect Drug Resist       Date:  2021-06-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.